stoxline Quote Chart Rank Option Currency Glossary
  
Novartis AG (NVS)
104.93  -0.79 (-0.75%)    06-17 16:00
Open: 104.44
High: 105.155
Volume: 972,642
  
Pre. Close: 105.72
Low: 104.23
Market Cap: 205,294(M)
Technical analysis
2024-06-17 5:25:25 PM
Short term     
Mid term     
Targets 6-month :  124.7 1-year :  145.65
Resists First :  106.76 Second :  124.7
Pivot price 103.96
Supports First :  101.91 Second :  98.91
MAs MA(5) :  105.34 MA(20) :  103.43
MA(100) :  100.18 MA(250) :  100.01
MACD MACD :  1.5 Signal :  1.5
%K %D K(14,3) :  85.8 D(3) :  86.9
RSI RSI(14): 59.8
52-week High :  108.77 Low :  92.19
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NVS ] has closed below upper band by 39.2%. Bollinger Bands are 30.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 105.2 - 105.91 105.91 - 106.49
Low: 102.85 - 103.55 103.55 - 104.13
Close: 103.9 - 105.04 105.04 - 105.98
Company Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Headline News

Mon, 17 Jun 2024
Trust Co. of Vermont Sells 8749 Shares of Novartis AG (NYSE:NVS) - Defense World

Mon, 17 Jun 2024
Novartis AG (NYSE:NVS) Shares Purchased by Wellington Management Group LLP - Defense World

Sun, 16 Jun 2024
Novartis AG (NYSE:NVS) Shares Bought by Fisher Asset Management LLC - MarketBeat

Sat, 15 Jun 2024
Novartis AG (NYSE:NVS) Shares Purchased by Osterweis Capital Management Inc. - Defense World

Sat, 15 Jun 2024
V Square Quantitative Management LLC Invests $848,000 in Novartis AG (NYSE:NVS) - MarketBeat

Sat, 15 Jun 2024
Novartis AG (NYSE:NVS) Sees Significant Decrease in Short Interest - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 2,040 (M)
Shares Float 1,950 (M)
Held by Insiders 0 (%)
Held by Institutions 6.9 (%)
Shares Short 5,130 (K)
Shares Short P.Month 3,810 (K)
Stock Financials
EPS 4.4
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 19.44
Profit Margin 31.9 %
Operating Margin 30.7 %
Return on Assets (ttm) 8.6 %
Return on Equity (ttm) 19.8 %
Qtrly Rev. Growth 9.6 %
Gross Profit (p.s.) 0
Sales Per Share 23.39
EBITDA (p.s.) 9.28
Qtrly Earnings Growth 21.5 %
Operating Cash Flow 13,770 (M)
Levered Free Cash Flow 13,390 (M)
Stock Valuations
PE Ratio 23.84
PEG Ratio 1.4
Price to Book value 5.39
Price to Sales 4.48
Price to Cash Flow 15.54
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android